Zhaoke Ophthalmology's Yuvezzi Approved as Clinically Urgent Imported Drug
Zhaoke Ophthalmology (HKG:6622) said its presbyopia drug Yuvezzi was approved for use at the Boao Super Hospital by the Hainan provincial government, according to a Hong Kong bourse filing Tuesday. The drug is designed to restore near vision lost due to presbyopia and was approved as a clinically urgent imported drug.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.